No abstract is available for this article. mehr
Um alle Funktionen dieser Seite zu nutzen, aktivieren Sie bitte die Cookies in Ihrem Browser.
Mit einem my.bionity.com-Account haben Sie immer alles im Überblick - und können sich Ihre eigene Website und Ihren individuellen Newsletter konfigurieren.
Hyperlipidemia and oxidative stress have been implicated as contributing factors to the development of atherosclerosis and cardiovascular diseases (CVDs). Currently, a large number of antihyperlipidemic medications are conveniently available in the market. Nonetheless, the majority of antihyperlipidemics lack the desired safety and efficacy. Thus, the present study was undertaken to evaluate the potential effect of novel N‐(benzoylphenyl)pyridine‐4‐carboxamide and N‐(9,10‐dioxo‐9,10‐dihydroanthracenyl)pyridine‐4‐carboxamide derivatives in controlling hyperlipidemia and oxidative stress using the Triton WR‐1339‐induced hyperlipidemic rat model for antihyperlipidemic activity and the DPPH radical scavenging assay for antioxidant activity. This study revealed the antihyperlipidemic activities of some of the newly synthesized, novel carboxamide derivatives, mainly C4 and C12 (p < 0.05). The majority of the compounds displayed a relatively low or no DPPH radical scavenging effect, with C20 possessing the best radical scavenging effect (22%) among all. This research opens the door for new potential antihyperlipidemic compounds derived from isonicotinic acid. N‐(3‐Benzoylphenyl)pyridine‐4‐carboxamide (C4) was found to have promising lipid‐lowering and antioxidant effects, which may create a protective effect against CVDs, by reducing the LDL‐C levels and diminishing the generation of reactive oxygen species.
Novel N‐(benzoylphenyl)pyridine‐4‐carboxamide and N‐(9,10‐dioxo‐9,10‐dihydroanthracenyl)pyridine‐4‐carboxamide derivatives were studied for their activities in controlling hyperlipidemia and oxidative stress. N‐(3‐Benzoylphenyl)pyridine‐4‐carboxamide showed promising lipid‐lowering and antioxidant effects, which may provide protection against cardiovascular diseases.
Abstract The single radial immunodiffusion assay has been the accepted method for determining the potency of inactivated influenza vaccines since 1978. The world‐wide adoption of this assay for vaccine standardisation was facilitated through collaborative studies that demonstrated a high ... mehr
Abstract Background Whether morbidity from the 1918‐19 influenza pandemic discriminated by socioeconomic status has remained a subject of debate for 100 years. In lack of data to study this issue recent literature have hypothesized that morbidity was “socially neutral”. Objectives ... mehr